Guggenheim analyst Subbu Nambi raised the firm’s price target on Twist Bioscience (TWST) to $50 from $42 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience: Operational Outperformance, NGS Reacceleration, and Discounted Valuation Support Buy Rating
- Twist reports preliminary Q1 revenue $103.7M +/- $0.2M, consensus $100.32M
- Private Markets: Anthropic raising $10B at $350B valuation
- Twist Bioscience price target raised to $43 from $32 at TD Cowen
- Twist Bioscience price target raised to $42 from $34 at Evercore ISI